Renee Saliby, MD, MSc, postdoctoral research fellow, Dana-Farber Cancer Institute, discusses the rationale for investigating the correlation between intermediate end points and overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with immune checkpoint inhibitors.

Website: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]
LinkedIn: [ Ссылка ]

свернуть